HC Wainwright Analysts Increase Earnings Estimates for KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a note issued to investors on Wednesday, February 18th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($1.17) for the quarter, up from their previous forecast of ($1.56). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.79) EPS and FY2026 earnings at ($3.64) EPS.

A number of other equities analysts have also commented on KPTI. Royal Bank Of Canada dropped their price objective on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 4th. The Goldman Sachs Group set a $12.00 target price on Karyopharm Therapeutics in a report on Wednesday, December 17th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald started coverage on shares of Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Karyopharm Therapeutics Price Performance

Karyopharm Therapeutics stock opened at $9.67 on Friday. Karyopharm Therapeutics has a fifty-two week low of $3.51 and a fifty-two week high of $10.38. The firm has a fifty day moving average price of $7.26 and a two-hundred day moving average price of $6.42. The firm has a market cap of $177.35 million, a price-to-earnings ratio of -0.58 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KPTI. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Karyopharm Therapeutics by 112.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after acquiring an additional 790,417 shares during the period. Corient Private Wealth LLC acquired a new position in Karyopharm Therapeutics in the fourth quarter worth about $74,000. Ikarian Capital LLC lifted its stake in Karyopharm Therapeutics by 1,897.9% during the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after purchasing an additional 517,297 shares during the period. Tudor Investment Corp ET AL bought a new position in Karyopharm Therapeutics during the fourth quarter worth about $95,000. Finally, Quadrature Capital Ltd acquired a new stake in Karyopharm Therapeutics during the fourth quarter valued at approximately $439,000. Institutional investors own 66.44% of the company’s stock.

Key Headlines Impacting Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: HC Wainwright raised Q1–Q4 2026 and FY2026 EPS forecasts (e.g., FY26 from ($5.25) to ($3.64)) and reiterated a “Buy” rating with a $15 price target — a clear analyst positive that can support upside versus the current sub‑$15 market price. Article Title
• Neutral Sentiment: Short interest entries show zero shares reported and a 0.0 days‑to‑cover ratio (with NaN increases noted) — the data appears anomalous and unlikely to be a meaningful driver until corrected/clarified by exchanges or reporting firms.
• Negative Sentiment: Shareholders approved a major increase in authorized shares — this creates a risk of future dilution (issuances for financing, partnerships or M&A), which typically weighs on share price unless proceeds fund clear value‑creating initiatives. Article Title

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.